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Effects of complement activation products on the synthesis of decay
accelerating factor and membrane cofactor protein by human mesangial
cells. We previously demonstrated that activation of terminal complement
components (C8 and/or C9) increases the synthesis and expression of
decay accelerating factor (DAF) on human glomerular cells. DAF is a cell
membrane-associated complement regulatory protein that inhibits com-
plement activation on cell surfaces. In the present studies we evaluated,
first, the mechanisms by which complement activation stimulates DAF
synthesis, and second, the effect of complement activation on the synthe-
sis, and expression of membrane cofactor protein (MCP), another com-
plement regulatory protein, by human mesangial cells (HMC) in culture.
Complement activation by immune complexes resulted in increased DAF
mRNA levels by at least two mechanisms: deposition of activated C3 on
HMC and generation of soluble complement activation products, specif-
ically C5a. The increase in DAF mRNA levels induced by activated C3 or
C5a was short lived (less than 4 hr). In contrast, the up-regulation of DAF
mRNA levels induced by activation of the complete complement cascade
persisted for at least eight hours. The effect of complement activation on
DAF mRNA levels was not affected by cycloheximide, a protein synthesis
inhibitor. However, cycloheximide alone resulted in a significant up-
regulation of DAF mRNA levels on HMC. In contrast to those findings,
complement activation did not cause an up-regulation of MCP mRNA,
nor an increase in the synthesis of this protein. However, by FACS,
complement produced a small but significant increase of MCP protein
levels on HMC. In conclusion, both MCP and DAF are present on HMC.
Several activated complement components are capable of increasing DAF
mRNA levels, but DAF protein levels increase only after activation of the
whole complement cascade. Complement activation has no effects on the
synthesis of MCP.
Complement activation on cell surfaces is inhibited by a series
of cell-associated complement regulatory proteins (C'RP) [1, 2],
and other components of the cell surface [3]. Cell associated C'RP
protect cells against complement mediated lysis [1] by inhibiting
complement activation either at the level of C3/C5 (C3-C'RP) or
C8/C9, Several characteristics of this protective function are of
interest. First, cytoprotection by C'RP has at least partial homol-
ogous restriction, that is, C'RP provide protection preferentially
against complement components of the same species as the cell [1,
2, 4, 5]. Second, in most cells, protection against complement
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mediated lysis is provided by the combined effects of several C'RP
[6—9]. Consistent with these observations, patients with congenital
deficiencies of several C'RP have more severe episodes of
hemolysis than patients with more selective deficiencies [8, 10].
Finally, more recent experiments have demonstrated that the
relative protective effects of each C'RP varies from cell to cell.
For example, in some cells, cytoprotection against complement is
provided mainly by DAF while in other cells protection is
provided mainly by MCP [11].
Most forms of glomerular disease in humans involve immune
complex (IC) formation and complement activation. Thus, fac-
tors, such as C'RP, that may protect glomerular cells against
complement mediated effects may influence the extent of tissue
damage that occurs during glomerulonephritis. Recently, we
investigated the mechanisms involved in the protection of human
glomerular cells from complement effects. In initial studies we and
others evaluated the presence of C3-C'RP in normal and diseased
human kidneys. All three known cell associated C3-C'RP, that is,
complement receptors type 1 (CR1), decay accelerating factor
(DAF), and membrane cofactor protein (MCP), are present in the
human kidney. CR1 is present exclusively on glomerular epithelial
cells [12]. DAF is present at low levels on glomerular cells from
normal kidneys and at higher levels in cells of the juxtaglomerular
apparatus [13]. In contrast, kidneys from patients with comple-
ment mediated glomerulonephritis demonstrated increased DAF
expression in glomeruli, interstitium and blood vessels [13].
Finally, MCP is present at high levels on renal tubular epithelial
cells and at lower levels in mesangial and endothelial cells. We
have not detected significant differences between the MCP stain-
ing of normal and diseased kidneys [14]. These findings suggest
that C3-C'RP may have a role in protecting kidney cells from
complement effects. In addition, during disease, glomerular cells
are induced to express more DAF and this effect may provide
additional protection against complement effects.
In subsequent studies, we have demonstrated that complement
activation increases DAF expression on the membrane of HMC in
vitro [15]. Furthermore, we have shown that: (1) The effect of
complement on DAF expression requires activation of terminal
complement components including C8 and/or C9. Specifically,
human serum deficient in C5 or C8 and soluble activated com-
plement components had no significant effects on DAF expres-
sion. (2) The increased expression of DAF on HMC exposed to
complement requires new RNA and protein synthesis. Based on
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these studies we postulated that complement activation increases
DAF gene transcription and DAF mRNA translation resulting in
increased cell membrane DAF expression. This postulate was
tested in the experiments described in the present manuscript.
Methods
Preparation of mesangial cell cultures and exposure to complement
activation products
Human mesangial cell (HMC) cultures were derived from
kidneys deemed unsuitable for transplantation. Cells used in the
present experiments were derived from five different adult kid-
neys. We have previously described the methods used for the
isolation and characterization of HMC [15, 16]. In brief, renal
cortex was minced and passed through progressively smaller-sized
sieves (Belico Glass Inc., Vineland, New Jersey, USA). Glomeruli,
retained by the last sieve, were treated with 0.1% collagenase
(Worthington Biochemical, Freehold, New Jersey, USA) and
cultured in plastic culture flasks (Corning Glass Works, Corning,
New York, USA) with media 199 (Gibco, Grand Island, New
York, USA) containing 10% Nu-serum (Collaborative Research,
Bedford, Massachusetts, USA) and antibiotics. Cellular out-
growths of the glomeruli were passed into new flasks and charac-
terized as described [15, 16].
To expose HMC to immune complex (IC) formation and
complement activation we used previously described methods
[15]. Briefly, confluent HMC layers were incubated first with
phenilated gelatin (DNP-GL), an antigen that binds avidly to
fibronectin present in the matrix produced by HMC in culture.
After removing the unbound DNP-GL, HMC were incubated with
rabbit IgG anti-DNP antibodies in the presence of 1:40 diluted
AB + human serum (HS) or HS deficient in specific complement
components (Quidel, San Diego, California). The dilutions of
complement deficient HS used in these experiments were such
that, once supplemented with the missing complement component
(Quidel), these sera produced the same degree of hemolysis of
antibody sensitized sheep erythrocytes as 1:40 diluted whole
HS [15]. In control experiments, HMC were incubated with: (1)
DNP-GL and HS; (2) DNP-GL in the presence of normal rabbit
IgG (Sigma) and HS; (3) rabbit anti-DNP antibodies and HS; and
(4) DNP-GL and anti-DNP antibodies in the absence of HS.
Unless otherwise indicated, these incubations were continued for
four hours.
In some experiments HMC were incubated with media or IC
and HS in the presence of cycloheximide (10 tg/ml) [15], a
protein synthesis inhibitor. Cycloheximide was added to the cells
together with the anti-DNP antibodies and HS and the incubation
was continued for four hours.
To test the effects of soluble activated complement compo-
nents, HMC were incubated with zymosan activated serum (ZAS)
[15] for four hours. Prior to addition to the culture all ZA sera
were heat inactivated at 56°C for 30 minutes. In other experi-
ments, HMC were incubated with recombinant C5a (rC5a)
(Sigma) suspended in media with 0.25% bovine serum albumin
(BSA). Control cells, in these experiments, were incubated for the
same period of time with 0.25% BSA.
The effects of complement on C3-C'RP synthesis might be due
to the binding of activated complement components to previously
unrecognized complement receptors on HMC. To test function-
ally for the presence of such putative receptors, HMC were
incubated for four hours with zymosan particles coated with
activated complement components. To prepare the complement
coated particles, zymosan particles (5 mg/mI) were incubated with
HS or heat inactivated serum (HIS) (both diluted 1:20) for 30
minutes at 37°C. Complement coated zymosan particles were
washed three times with sterile culture media and then added to
HMC flasks (5 mg/flask).
Isolation of HMC RNA and Northern blot analysis of DAF and
MCP messenger RNA (mRNA)
HMC were cultured for 7 to 10 days in 150 cm2 flasks and then
exposed to IC formation and complement activation products as
described above. At the end of the incubation, HMC were
detached from the culture flask by incubation with 0.25% Trypsin/
0.56 mivi EDTA (Gibco) for 10 minutes and washed with sterile
media. HMC RNA was isolated following the RNAzol method
(Cinna/Biotex Laboratories International, Inc., Friendswood,
Texas, USA) described previously [17, 18]. Total RNA concen-
tration was measured by light absorption at 260 nm. For Northern
blot analysis [18], 15 to 25 sg of RNA was loaded in each lane of
a 1% agarose gel and the RNA was separated by electrophoresis.
RNA was transferred to nylon membranes (Hybond-N, Amer-
sham) by capillary action. DAF and MCP mRNAs were identified
by hybridization of nylon membranes with 32P labeled DAF
eDNA [19] and MCP cDNA [20] (gifts from Dr. J.P. Atkinson,
Washington University, St. Louis, Missouri, USA). Following
autoradiography, the amount of DAF mRNA was quantitated by
densitometry (Pharmacia LKB. UltraScan L). The amount of total
RNA in each lane of the gel was quantitated by densitometry of
18s and 28s ribosomal RNA bands stained with ethidium bromide
(EB). To correct for variations in RNA loading, densitometry
values for DAF mRNA were divided by densitometry values of
total RNA (18s band) in the same lane. Changes in the amount of
DAF mRNA in stimulated MC are expressed as percent of the
DAF mRNA in MC incubated under control conditions.
Quantitation of DAF and MCP by flow cytometiy (FACS)
In these experiments, HMC were incubated under the various
conditions described above for four hours. Subsequently, HMC
were detached by incubation with Trypsin/EDTA and maintained
at 4°C. HMC were incubated with mouse monoclonal anti-DAF
antibodies (lAb, a gift from Dr. V. Nussenzweig), mouse mono-
clonal anti-MCP antibodies (GB24, a gift from Dr. J.P. Atkinson)
or irrelevant monoclonal antibodies. After a 30-minute incuba-
tion, HMC were washed three times and incubated with FITC-
labeled sheep anti-mouse IgG (Zymed) for 30 minutes. At the end
of the incubation, HMC were fixed with 1% paraformaldehyde
and analyzed by FACS [21]. Both the percent of FITC positive
HMC and the relative fluorescence intensity of cells, assessed in a
linear scale, were determined. Nonspecific staining was assessed
in HMC incubated with irrelevant monoclonal antibodies and
FITC labeled secondary antibodies, Nonspecific values were
subtracted from values obtained from cells stained with anti-DAF
or anti-MCP antibodies to obtain specific values.
Quantitation of HMC MCP by radioimmunoassay
We used the same methods previously described for the quan-
titation of DAF on HMC [15]. This method of quantitation was
used, in addition to FACS, because for the RIA HMC do not need
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Fig. 1. Top. DAF mRNA in HMC incubated with media and HIS for
4 hours (lane A), IC and HSfor 2 hours (lane B), 4 hours (lane C), 6 hours
(lane D) or 8 hours (lane E). Autoradiograph was developed for 7 days.
Bottom. EB fluorescence of 18S ribosomal RNA on the same gel
demonstrating uniform RNA loading.
to be exposed to trypsin prior to quantitation. Thus, any possible
effects of trypsin on MCP are avoided. Briefly, HMC were
incubated with media and HS, IC and HIS, IC and HS and IC and
HS in the presence of cycloheximide (10 gIml). At the end of the
incubation, HMC were washed with cold (4°C) media and main-
tained at that temperature during the following steps: (1) incuba-
tion, for 30 minutes, with mouse monoclonal anti-MCP antibodies
(0B24, a gift from Dr. J.P. Atkinson) [22, 23], diluted in 3% BSA
and 0.05% Tween; (2) after removing the unbound primary
antibody, HMC were incubated, for 45 minutes, with 125J labeled
rabbit anti-mouse IgG, diluted in the same media as the primary
antibody; (3) HMC were then washed, detached from the culture
wells by incubation with Trypsin/EDTA and the mixture was
counted for radioactivity. Subsequently, HMC were separated
from the supernatant by centrifugation and counted in a hemo-
cytometer. Results were expressed as pg of secondary antibody
per io HMC. In each experiment, control cells were incubated
first, with irrelevant monoclonal antibodies and then with 125J
labeled secondary antibodies [15]. Antibodies were radiolabeled
by the lodo-Gen method (Pierce Chemical Co., Rockford, Illinois,
USA).
Analysis of data
Data are expressed throughout the manuscript as mean
standard error of the mean. Data were analyzed by ANOVA, with
a Bonferroni post-t-test, or paired f-test as indicated in the text.
Results
Effects of complement activation on HMC DAF mRNA levels
HMC were exposed to IC formation and complement activa-
tion and DAF mRNA was analyzed by Northern blotting tech-
niques. As demonstrated in Figure 1, exposure to complement
activation products for two to eight hours was associated with a
progressive increase in DAF mRNA levels in HMC. By densitom-
etry of values obtained in this particular experiment, the increase
in DAF mRNA 2.2 kb transcript at 2, 4, 6, and 8 hours was 123%,
169%, 202%, and 218% of control values, respectively.
Previous studies have identified at least three different DAF
mRNA transcripts of 2.2, 1.6 and 1.5 Kb [24] (Fig. 1). All these
transcripts were identified on HMC although in most Northern
gels the 1.5 and 1.6 transcript are too close for easy identification.
Exposure to complement activation for four hours caused signif-
icant increases in both the 2.2 Kb (249 32% of control, N = 20)
and the 1.5 to 1.6 Kb (244 38%, N = 20) DAF mRNA
transcripts. In all subsequent experiments, densitometry data is
based on analysis of the 2.2 Kb DAF mRNA transcript. In control
experiments, we found that compared to HMC incubated with
media, HMC DAF mRNA levels were not significantly affected by
antigen alone, IC alone or HS alone (data not shown).
To further characterize the effects of complement activation
products, HMC were exposed to IC and human serum or IC and
human serum deficient in C3, C5 or C8. IC formation in the
presence of C3 deficient serum had no significant effects on DAF
mRNA levels (98 28%, N 5). In contrast, IC formation in the
presence of HS, CS deficient or C8 deficient serum (Fig. 2) caused
significant increases in DAF mRNA levels (213 21, N = 23;
178 24%, N = 7; 218 43%, N = 5, respectively, ANOVA P
<0.0001 compared to DAF mRNA levels in unstimulated cells).
C5 deficient had a tendency to produce a smaller increase in DAF
mRNA levels than whole HS; however, these differences did not
reach statistical significance. To further analyze the induction of
DAF mRNA by CS deficient serum, HMC were incubated with IC
and C5 deficient serum for variable periods of time (Fig. 3). As
can be seen, activation of C5 deficient serum induced a peak
increase in DAF mRNA levels after two hours of incubation, and
DAF mRNA levels decreased thereafter. Values obtained by
densitometry of the 2.2 Kb transcript in this particular Northern
included: 1 hour, 94%; 2 hours, 187%; 3 hours, 131%; 6 hours,
117% of control. These findings imply that activation of C3 is
required and is sufficient to up-regulate DAF mRNA levels. To
assess whether the effects of activated C3 were mediated by
previously undetected HMC receptors for C3 products, HMC
were incubated with zymosan particles coated with activated
complement products. These particles had no significant effects
on DAF mRNA levels (DAF mRNA levels, 92 10%, N = 4).
To test the effects of soluble activated complement components
on DAF mRNA levels, HMC were incubated with zymosan
activated sera. ZAS produced a significant up-regulation of DAF
mRNA levels (262 108, N = 5), although the degree of DAF
mRNA up-regulation was quite variable among experiments. To
determine which soluble complement component was responsible
for the effects of ZAS on DAF mRNA, HMC were incubated with
increasing doses of rC5a. The anaphylatoxin rC5a significantly
up-regulated DAF mRNA levels and the effects of rC5a were dose
dependent with a maximum increase in DAF mRNA levels
occurring after incubation with 2 g/ml (215%) (Fig. 4). Subse-
quently we showed that, in most experiments, incubation of HMC
with rCSa for variable periods of time (Fig. 5) caused a peak
induction of DAF mRNA after two hours of incubation followed
by a decline in DAF mRNA levels.
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Fig. 2. Top. DAF mRWA in HMC incubated for
4 hours with media and HS (lane A), IC and HS
(lane B), IC and C5 deficient serum (lane C), or
IC and C8 deficient serum (lane D).
Autoradiograph exposed for 5 days. Bottom.
EB fluorescence of 18S ribosomal RNA on the
same gel demonstrating uniform RNA loading.
Fig. 3. Top. Northern blot of DAF mRNA
isolated from HMC incubated with IC and C5
deficient serum for B, 1 hour; C, 2 hours;
D, 4 hours; E, 6 hours. A, control lane.
Autoradiograph exposed for 2 days. Bottom.
EB fluorescence of 18S ribosomal RNA on the
same gel demonstrating uniform RNA loading.
Role of protein 5ynthesis on DAF transcription each condition). Compared to control cells incubated with media
To assess whether the effects of complement activation on DAF and HIS, incubation with IC and HS caused an increase in DAF
mRNA levels required protein synthesis, in the next series of mRNA levels (193 39%). However, the effects of IC and HS
experiments HMC were incubated with media alone or IC and HS were not significantly affected by eycloheximide (207 35%). In
in the presence or absence of cycloheximide (10 gJml; N =4 for addition, cycloheximide alone caused a significant up-regulation
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Table 1. FACS analysis of DAF and MCP levels on HMC membranes
following exposure to IC formation and complement activation
Parameter Antigen (N)'
Incubation conditions .Paired
(P)Media + HS IC + HS
Positive cells %
FITC intensity1'
DAF (5)
DAF (5)
41 5
59 14
62 7
202 47
0.006
0.02
Positive cells % MCP (3) 77 3 83 3 0.05
FITC intensity MCP (3) 144 14 282 24 0.05
a N represents the number of experimentsbFITC intensity was measured by arbitrary fluorescence units
Fig. 4. Top. Effects of increasing amounts of rC5a on DAF mRNA levels:
(A) cell incubated without rC5a; (B) cells incubated for 4 hours with rC5a at
0.5 ig/ml; (C) rC5a at I pg/ml; (D) rC5a at 2 sg/ml; (E) rC5a at 4 1igImL
Bottom. EB fluorescence of 18S ribosomal RNA on the same gel
demonstrating uniform RNA loading.
Fig. 5. Top. Northern blot analysis of DAF mRNA isolated from HMC
incubated with rC5a (2 1uglml) for B, 1 hour; C, 2 hours; D, 4 hours; E,
6 hours. A, DAF mRNA in control cells incubated with media alone.
Autoradiograph exposed for 4 days. Bottom. EB fluorescence of 18S
ribosomal RNA on the same gel.
of DAF mRNA levels (198 35%), suggesting that in unstimu-
lated HMC, DAF mRNA levels may be suppressed by a control
mechanism that requires protein synthesis.
Effects of complement activation on DAF and MCP protein
expression on HMC
In these experiments we first used FACS analysis to determine
the effect of complement activation on DAF and MCP protein
levels on the HMC membrane (Table 1). As can be seen, both
DAF and MCP are present on unstimulated HMC. Following
complement activation for four hours, the percent of cells positive
for DAF and the amount of DAF per cell (fluorescence intensity)
are significantly increased. Similarly, MCP levels on HMC are
increased after exposure to complement activation products al-
though the changes in MCP are of lesser magnitude than the
changes in DAF.
We next assessed MCP levels on HMC by RIA. By ANOVA
there were no statistically significant differences in MCP levels in
HMC incubated with: (1) HS alone (30.7 5 pg Ab/103 cells),
(2) IC + HIS (40.8 10 pg Ab/103 cells); (3) IC + HS (49.3 10
pg Ab/103 cells); and (4) IC + HS in the presence of cyclohexi-
mide (41.8 9 pg Ab/103 cells) (ANOVA P = 0.4). Thus, the
effects of complement activation on HMC MCP are not depen-
dent on protein synthesis. To further assess the effects of comple-
ment activation on MCP synthesis, MCP mRNA levels were
analyzed on HMC exposed to IC formation and complement
activation. Complement activation had no significant effect on
MCP mRNA levels (data not shown).
Discussion
In the present study we demonstrated that deposition of
activated complement components on HMC increases DAF
mRNA levels and, under certain circumstances, increases DAF
protein levels on the HMC membrane. In contrast, under the
same conditions, complement activation does not increase the
synthesis of a second C3-C'RP, MCP.
Complement activation up-regulates DAF mRNA levels by at
least two mechanisms: (1) deposition of activated C3 products on
HMC, and (2) generation of soluble activated complement prod-
ucts. The evidence for a role of C3 deposition is as follows: IC
activation of C5 deficient serum, that is, activation of the classical
complement pathway including C3, increased DAF mRNA levels.
In contrast, IC activation of C3 deficient serum had no significant
effects on DAF mRNA levels, indicating that the effect of C5
deficient serum is due to activation of C3. The effect of activated
C3 on DAF mRNA levels suggests that HMC may have the
capacity to bind degradation products of C3 generated extrinsi-
cally to the cell membrane. However, previous studies [12, 15, 25,
26] and the findings of the present studies provide no evidence for
the presence of C3 receptors on HMC. Two other possible
mechanisms may explain signal transduction via C3 deposition on
cell membranes: (1) We speculate that the binding of activated C3
(C3b) to plasma membrane proteins may generate intracellular
signals. Although there is no direct evidence for this effect of
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activated C3, previous studies showed that activated complement
components, earlier that C7, can cause changes in intracellular
mediators such as calcium and cAMP [271. (2) It has been
demonstrated that binding of certain monoclonal antibodies to
DAF may generate signal transduction [28]. The participation of
these mechanisms in the regulation of DAF mRNA levels by C3
remain speculative.
ZAS caused an up-regulation of DAF mRNA levels and this
effect could be accounted for, at least in part, by the effects of C5a
on HMC. However, the present studies do not exclude an effect
mediated via C3a. These findings may indicate the presence of
receptors for C5a on HMC. In addition, a previous study suggest
that the binding of anaiphylatoxins to cells may be charge
dependent and not receptor mediated [29]. Similar to the effects
of C5a on DAF [151, in other cell systems CSa increases transcrip-
tion but not translation of other proteins [30]. The doses of rC5a
used in these previous experiments is in the range of doses used in
the previous study. To our knowledge the presence of C5a
receptors on HMC has not been explored. However, injections of
C5a into the kidney result in significant changes in glomerular
filtration rate perhaps due to mesangial cell contraction [31]. In
addition, it has been suggested that C5a may cause hemodynamic
alterations in the diseased glomerulus [32].
The present results complement previous findings from our
laboratory demonstrating that activation of terminal complement
components (C8 and/or C9) induces an increase in DAF protein
levels on HMC, an effect that requires RNA and protein synthesis
[151. In those previous studies we also showed that ZAS and
activation of C5 deficient serum have no significant effects on
DAF protein. In contrast, we showed here that those incubations
cause an increase in DAF mRNA. Overall, these observations
suggest that although early complement components (activated
C3 and C5a) cause an increase in DAF mRNA, terminal comple-
ment components may initiate a more complex signal that also
causes an increase in DAF mRNA translation resulting in an
increase in DAF levels on the cell membrane. It should also be
noted that activation of terminal complement components causes
a more long standing up-regulation of DAF mRNA levels than
activation of early complement components, and perhaps these
differences have an impact on DAF synthesis. The present study
also demonstrates that DAF mRNA levels are increased after
incubation of unstimulated HMC with protein synthesis inhibi-
tors. These effects of cycloheximide may be due to an increase in
mRNA half life [33], or by preventing the synthesis of an inhibitor
of gene transcription [341. Thus, it appears that in unstimulated
HMC, DAF mRNA levels are maintained low by a process that
requires protein synthesis.
The relative cytoprotective role of DAF and MCP varies among
cells [11]. MCP levels on HMC are higher than DAF levels.
However, as shown here, HMC can increase DAF levels, and
presumably cytoprotection, when under complement attack. Fur-
ther dissection of the signal transduction pathways that control
DAF synthesis on HMC and other cells may suggest strategies
that will permit us to modulate cytoprotection against comple-
ment effects. Because glomerular diseases are frequently associ-
ated with complement deposition, modulation of C'RP levels on
glomerular cells may have beneficial effects in complement medi-
ated diseases.
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